{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle",
    "query": {
      "intervention": "One cycle"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2754,
    "total_pages": 276,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T13:16:17.665Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02509546",
      "title": "8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "8-Chloroadenosine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-09-02",
      "completion_date": "2021-03-16",
      "has_results": true,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02509546"
    },
    {
      "nct_id": "NCT00759317",
      "title": "Physiologic Monitoring of Antidepressant Treatment Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "venlafaxine (Effexor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2001-06",
      "completion_date": "2002-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-03",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00759317"
    },
    {
      "nct_id": "NCT06660017",
      "title": "Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ketamine Topical",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 62,
      "start_date": "2026-09",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06660017"
    },
    {
      "nct_id": "NCT03879408",
      "title": "Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "440 mg naproxen sodium with 1000 mg acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "220 mg naproxen sodium with 650 mg acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "10 mg hydrocodone + 650 mg acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "440 mg naproxen sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "17 Years to 50 Years"
      },
      "enrollment_count": 290,
      "start_date": "2019-05-28",
      "completion_date": "2019-11-13",
      "has_results": true,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03879408"
    },
    {
      "nct_id": "NCT05616624",
      "title": "ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2023-04-05",
      "completion_date": "2026-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • St Louis, Missouri • Fairfax, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05616624"
    },
    {
      "nct_id": "NCT04611880",
      "title": "Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-01-25",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04611880"
    },
    {
      "nct_id": "NCT02346526",
      "title": "A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Castration-resistant Prostate Cancer Metastatic to Bone"
      ],
      "interventions": [
        {
          "name": "Blood Tests",
          "type": "PROCEDURE"
        },
        {
          "name": "CT scan",
          "type": "PROCEDURE"
        },
        {
          "name": "FACBC PET/MRI in a subset of participants",
          "type": "PROCEDURE"
        },
        {
          "name": "Radium-223 dichloride",
          "type": "DRUG"
        },
        {
          "name": "bone scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2015-04",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2022-09-29",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346526"
    },
    {
      "nct_id": "NCT05415150",
      "title": "Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Thrombolytic Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-02-18",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05415150"
    },
    {
      "nct_id": "NCT01280591",
      "title": "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 440 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "DPH 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 712,
      "start_date": "2010-10",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280591"
    },
    {
      "nct_id": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma or Advanced Solid Tumors",
        "Melanoma",
        "Uveal Melanoma",
        "P53 Mutation",
        "MDM2 Gene Mutation",
        "Cutaneous Melanoma",
        "Mucosal Melanoma",
        "Malignant Peripheral Nerve Sheath Tumors (MPNST)"
      ],
      "interventions": [
        {
          "name": "Phase 1b: APG-115+pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2018-08-29",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-08T13:16:17.665Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611868"
    }
  ]
}